SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ZVRA

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

US · Delayed Price · Currency is USD
Also listed: KMPHHealthcare · Biotechnology
$8.76-$0.31 (-3.42%)
 
Market cap
$521M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 16, 2015
Website
Market Cap$521.26M+1.3%
Revenue (ttm)$147.76M+75.1%
Net Income$78.02M+120.8%
EPS$1.20+92.6%
Shares Out59.50M
PE Ratio6.84
Forward PE9.87
Dividendn/a
Ex-Dividend Daten/a
Volume1,152,866
Open$8.95
Previous Close$9.07
Day's Range$8.70 - $9.17
52-Week Range$8.01 - $15.04
Beta0.99
AnalystsBuy
Price Target$24.25(+176.83%)
Earnings DateMar 8, 2027

About ZVRA

Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.

Address
101 Federal Street, Boston, MA, 02110, US
Market Cap
521 million
Employees
61
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$2.73M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Strong
From ZVRA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-3.42%
5 Days
-3.84%
1 Month
-15.20%
6 Months
-12.66%
1 Year
+1.27%

$ZVRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ZVRA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ZVRA's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ZVRA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ZVRA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ZVRA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ZVRA

VTIVanguard Morningstar Total Stock Market ETF$15.39M
IWMiShares Russell 2000 ETF$13.85M
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF$6.97M
VXFVanguard Extended Market ETF$6.93M
XPHState Street SPDR S&P Pharmaceuticals ETF$6.89M
IBBiShares Biotechnology ETF$4.10M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ZVRA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
28

News check: Negative EU regulatory opinion on lead drug overshadows analyst optimism; significant setback for European market prospects.

Recent Insider Activity

Buys
0
Sells
14
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-35.0 since Aug 21
0255075100Aug 21 — Insider Score 35.0Aug 22 — Insider Score 35.0Aug 23 — Insider Score 35.0Aug 24 — Insider Score 35.0Aug 25 — Insider Score 35.0Aug 26 — Insider Score 35.0Aug 27 — Insider Score 35.0Aug 28 — Insider Score 35.0Aug 29 — Insider Score 35.0Aug 30 — Insider Score 35.0Aug 31 — Insider Score 35.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 24.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

XPHState Street SPDR S&P Pharmaceuticals ETF1.57%
FDLSInspire Fidelis Multi Factor ETF0.97%
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF0.88%
JSMLJanus Henderson Small Cap Growth Alpha ETF0.81%
QQQSInvesco NASDAQ Future Gen 200 ETF0.57%
BRSVEA Series Trust - EA Bridgeway Select Small-Cap Value ETF0.39%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.24%
BFORALPS ETF Trust - Barron's 400 ETF0.23%
SFLOVictoryShares Small Cap Free Cash Flow ETF0.23%
ROSCHartford Multifactor Small Cap ETF0.18%
IWCiShares Micro-Cap ETF0.17%
FSCCFederated Hermes MDT Small Cap Core ETF0.16%

Weight is the stock’s share of each fund’s holdings.